MEDI-0618

N/A

Report date: 2026/03/16 20:01:47

Base Information

Drug NameMEDI-0618
Drug Alias NameMEDI-0618MEDI0618ABBV-2002ABBV2002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProtease-activated receptor-2 antagonists
TargetsProtease-activated receptor-2
Therapy Area/IndicationsChronic PainMigraine Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesPoland +[9
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesAstrazeneca Plc
Active IndicationsMigraine Disorders
Inactive IndicationsChronic Pain

Other Information

ATC CodeN/A
Related LinksN/A